<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135652</url>
  </required_header>
  <id_info>
    <org_study_id>CRLM-AR1</org_study_id>
    <nct_id>NCT03135652</nct_id>
  </id_info>
  <brief_title>Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation</brief_title>
  <official_title>Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized phase II trial to evaluate the efficacy of adjuvant consolidative
      radiotherapy in colorectal cancer liver metastasis (CRLM) patients after chemotherapy
      combined with surgical resection or radiofrequency ablation of liver lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver metastases are detected in 40-50% of patients diagnosed with colorectal cancer. Local
      treatments like surgical resection or radiofrequency ablation result in 5-year survival of
      35%. However, relapse still occurs in 70% of patients. Stereotactic body radiotherapy (SBRT)
      has emerged as a valid treatment not only to provide excellent symptom palliation, but also
      is effective in local control of metastatic lesions and improves survival. The potential
      efficacy of SBRT as adjuvant radiotherapy in CRLM patients after surgical resection or
      radiofrequency ablation is still unknown.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>adjuvant radiotherapy:SBRT chemotherapy:mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the effect of consolidative SBRT of liver lesions versus observation on disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate overall survival after consolidative SBRT in comparison to observation alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic disease free survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate Intrahepatic disease free survival after consolidative SBRT in comparison to observation alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Acute toxicity was scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria during and up to 3 months after radiotherapy. Late toxicity was graded using the Radiation Therapy Oncology Group (RTOG)/European Organisation for the Research and Treatment of Cancer (EORTC) criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Radiotherapy</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>adjuvant SBRT</intervention_name>
    <description>adjuvant SBRT of liver lesions</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment</description>
    <arm_group_label>chemoradiotherapy</arm_group_label>
    <arm_group_label>chemotherapy</arm_group_label>
    <other_name>neoadjuvant chemotherapy and adjuvant chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biopsy proven unresectable metastatic colorectal cancer (CRC)

          2. Primary resection of colorectal cancer (CRC)

          3. Age≥18 years

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          5. Absence of evidence of extra-hepatic diseases

          6. 1 to 3 liver metastases with an individual maximum diameter of up to 5 cm

          7. Metastatic liver lesions receiving R0 or R1 resection or radiofrequency ablation with
             visible tumor bed

          8. Aspartate aminotransferase, alanine aminotransferase &amp; alkaline phosphates must be ≤
             2.5 times of the upper limit of normal. Total bilirubin must be within the limit of
             normal.

          9. Patients should have adequate bone marrow function as defined by peripheral
             granulocyte count of ≥1500/mm3.

         10. Patients must provide verbal and written informed consent to participate in the study.

         11. Absence of any severe pulmonary or cardiac diseases

        Exclusion Criteria:

          1. Patients with either untreated brain metastases or brain metastases treated within the
             past three months are ineligible

          2. Patients who are pregnant

          3. Patients with severe organ dysfunction

          4. History of liver radiotherapy

          5. Unwillingness to participate or inability to comply with the protocol for the duration
             of the study

          6. Participation in any investigational drug study within 3 months preceding the start of
             study treatment

          7. Patients not suitable to take part in clinical trials judged by researches
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao Zhang, MD</last_name>
    <phone>862785871982</phone>
    <email>1277577866@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhang, MD, PHD</last_name>
      <phone>862785871982</phone>
      <email>1277577866@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhenyu Lin, MD</last_name>
      <phone>15827130393</phone>
      <email>tojilin@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996 Apr 1;77(7):1254-62.</citation>
    <PMID>8608500</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.</citation>
    <PMID>27789196</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Tao Zhang</investigator_full_name>
    <investigator_title>Chief of Gastrointestinal Oncology Department</investigator_title>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Liver Metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

